Literature DB >> 15547441

Intratympanic steroid treatment: a review.

Karen Jo Doyle1, Christopher Bauch, Robert Battista, Charles Beatty, Gordon B Hughes, John Mason, Jennifer Maw, Frank L Musiek.   

Abstract

OBJECTIVE: To review published literature regarding the use of intratympanic steroids in the treatment of Meniere's disease and sudden sensorineural hearing loss and to make recommendations regarding their use based on the literature review. DATA SOURCES: Literature review from 1996 to 2003, PubMed, Medline Plus, and Web of Science. STUDY SELECTION: Retrospective case series and uncontrolled prospective cohort studies were the only types of studies available for review.
CONCLUSION: On the basis of the available literature, a weak recommendation is made to use intratympanic steroid treatment of sudden hearing loss if oral steroid therapy fails or is contraindicated. The available studies regarding intratympanic steroid treatment of Meniere's disease and tinnitus are inadequate to answer the question of the efficacy of this treatment for these conditions. Higher quality studies are needed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15547441     DOI: 10.1097/00129492-200411000-00031

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  14 in total

1.  Comparison of the protective efficacy between intratympanic dexamethasone and resveratrol treatments against cisplatin-induced ototoxicity: an experimental study.

Authors:  Gökçe Simsek; Burak Mustafa Taş; Nuray Bayar Muluk; Musa Azman; Rahmi Kılıç
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-09-17       Impact factor: 2.503

2.  The protective effects of intratympanic dexamethasone and vitamin E on cisplatin-induced ototoxicity are demonstrated in rats.

Authors:  Mustafa Paksoy; Emin Ayduran; Arif Sanlı; Mehmet Eken; Sedat Aydın; Zeynep Alev Oktay
Journal:  Med Oncol       Date:  2010-03-19       Impact factor: 3.064

Review 3.  Corticosteroid therapy for hearing and balance disorders.

Authors:  Dennis R Trune; Barbara Canlon
Journal:  Anat Rec (Hoboken)       Date:  2012-10-08       Impact factor: 2.064

4.  Blocking the glucocorticoid receptor with RU-486 does not prevent glucocorticoid control of autoimmune mouse hearing loss.

Authors:  Dennis R Trune; J Beth Kempton
Journal:  Audiol Neurootol       Date:  2009-11-16       Impact factor: 1.854

5.  Microfabricated reciprocating micropump for intracochlear drug delivery with integrated drug/fluid storage and electronically controlled dosing.

Authors:  Vishal Tandon; Woo Seok Kang; Tremaan A Robbins; Abigail J Spencer; Ernest S Kim; Michael J McKenna; Sharon G Kujawa; Jason Fiering; Erin E L Pararas; Mark J Mescher; William F Sewell; Jeffrey T Borenstein
Journal:  Lab Chip       Date:  2016-03-07       Impact factor: 6.799

6.  Cisplatin-induced ototoxicity: effect of intratympanic dexamethasone injections.

Authors:  Gerhard W Hill; D Kent Morest; Kourosh Parham
Journal:  Otol Neurotol       Date:  2008-10       Impact factor: 2.311

Review 7.  Optimal management of Ménière's disease.

Authors:  Carol A Foster
Journal:  Ther Clin Risk Manag       Date:  2015-02-25       Impact factor: 2.423

8.  Comparative Analysis of the Combined Therapeutic Effects of Lipoprostaglandin E1 on Sudden Idiopathic Sensorineural Hearing Loss.

Authors:  Haeng Seon Shim; Joon Soo Kim; Myung Gu Kim
Journal:  J Audiol Otol       Date:  2017-03-30

9.  Betahistine in the treatment of Ménière's disease.

Authors:  Michel Lacour; Paul H van de Heyning; Miroslav Novotny; Brahim Tighilet
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

Review 10.  An overview of pharmacology and clinical aspects concerning the therapy of cochleo-vestibular syndromes by intratympanic drug delivery.

Authors:  Felician Chirteş; Silviu Albu
Journal:  Clujul Med       Date:  2013-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.